Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report

Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report

Microsatellite instability-high (MSI-H) is widely believed to be a biomarker for immune checkpoint inhibitors (ICIs) such as pembrolizumab in solid tumors. However, due to the low prevalence of MSI-H in most cancers, it tends to be insufficient to identify whether patients should receive ICIs accord...

Full description

Bibliographic Details
Main Authors:	Tian Zeng, Lei Zhang, Can Chen, Xiang Zhao, Xiaoqing Liu, Fengwei Ran, Tingting Yong, Ying Yang, Henghui Zhang, Yanling Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-11-01
Series:	Frontiers in Oncology
Subjects:	esophageal squamous cell carcinoma microsatellite instability pembrolizumab complete response DNA damage repair
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.767957/full

Similar Items

Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma
by: Masaya Senda, et al.
Published: (2023-11-01)

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
by: Motohiro Fujiwara, et al.
Published: (2020-03-01)

Successful pembrolizumab treatment of microsatellite instability‐high intrahepatic cholangiocarcinoma: A case report
by: Yuki Ikeda, et al.
Published: (2021-04-01)

Loss of heterozygosity and microsatellite instability as predictive markers among Iranian esophageal cancer patients
by: Mohammad Mahdi Forghanifard, et al.
Published: (2016-07-01)

Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort
by: Wei‐Xiang Qi, et al.
Published: (2023-06-01)

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
by: Takumi Kageyama, et al.
Published: (2022-11-01)

Pathological Complete Response of Clinical T4b Ascending Colon Cancer after Preoperative Chemotherapy Using Pembrolizumab
by: Terufumi Yoshida, et al.
Published: (2021-10-01)

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab
by: Fanny Zulay Acero Brand, et al.
Published: (2018-03-01)

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
by: Michael M. Boyiadzis, et al.
Published: (2018-05-01)

Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
by: Yannan J. Wang, et al.
Published: (2021-02-01)

Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report
by: Maia L. Valls, et al.
Published: (2022-06-01)

Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States
by: Jia Hu, et al.
Published: (2022-12-01)

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)
by: Hongtao Duan, et al.
Published: (2022-06-01)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More
by: Zhiwei Zheng, et al.
Published: (2022-06-01)

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer
by: Tan Chongqing, et al.
Published: (2021-12-01)

Circulating Tumor DNA-Based Detection of Microsatellite Instability and Response to Immunotherapy in Pancreatic Cancer
by: Saivaishnavi Kamatham, et al.
Published: (2020-02-01)

Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review
by: Akihiro Takeda, et al.
Published: (2020-05-01)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China
by: Zhang X, et al.
Published: (2023-09-01)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first‐line treatment for advanced esophageal cancer
by: Zhuo‐Miao Ye, et al.
Published: (2023-03-01)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
by: Qiao Liu, et al.
Published: (2022-01-01)

Metachronous cutaneous squamous cell carcinoma in a young patient as the only presenting symptom to uncover Lynch syndrome with MLH1 Germline mutation
by: Karam Khaddour, et al.
Published: (2020-11-01)

Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case report
by: A. A. Rumyantsev
Published: (2021-12-01)

Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting
by: Yi-Xin Zhou, et al.
Published: (2021-09-01)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
by: Wenyu Yang, et al.
Published: (2023-04-01)

Squamous Cell Carcinoma of the Lung With Microsatellite Instability in a Patient With Lynch Syndrome: A Case Report
by: Emna Haddad, MD, et al.
Published: (2024-01-01)

Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
by: Guihong Liu, et al.
Published: (2024-03-01)

Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study
by: Mei Zhan, et al.
Published: (2022-03-01)

Comparative transcriptome characterization of esophageal squamous cell carcinoma and adenocarcinoma
by: Xianfeng Li, et al.
Published: (2023-01-01)

Characterization of Esophageal Microbiota in Patients With Esophagitis and Esophageal Squamous Cell Carcinoma
by: Zongdan Jiang, et al.
Published: (2021-11-01)

Change in Maximal Esophageal Wall Thickness Provides Prediction of Survival and Recurrence in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy and Surgery
by: Wu Y, et al.
Published: (2021-03-01)

Esophageal squamous cell carcinoma presenting as a submucosal tumor
by: Lin Yang, et al.
Published: (2023-08-01)

Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial designCentral MessagePerspective
by: Yuyan Zheng, MD, et al.
Published: (2022-03-01)

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study
by: Wenqun Xing, et al.
Published: (2021-12-01)

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
by: Tsukasa Yoshida, et al.
Published: (2022-09-01)

Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab
by: Naoki Kadota, et al.
Published: (2022-08-01)

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
by: Åse Bratland, et al.
Published: (2023-11-01)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
by: Kazuki Gohara, et al.
Published: (2021-01-01)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
by: Ying Cheng, MD, et al.
Published: (2021-10-01)

A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma
by: Yu Yang, et al.
Published: (2024-04-01)

Genomic instability in human actinic keratosis and squamous cell carcinoma
by: Luciana Sanches Cabral, et al.
Published: (2011-01-01)